On the cusp of targeted therapy for cancer cachexia — what clinical benefits might we promise our patients?

IF 81.1 1区医学 Q1 ONCOLOGY

Nature Reviews Clinical Oncology Pub Date : 2024-11-05 DOI:10.1038/s41571-024-00964-1

Vickie E. Baracos

引用次数: 0

Abstract

A number of therapeutics that target mediators of signalling in the hypothalamic and brainstem regions that control appetite, ingestive behaviour, satiety, nausea and vomiting are starting to move the needle on cancer cachexia. However, clarification of meaningful clinical benefits for patients and the primary end points that should support regulatory approval of cachexia treatments is needed.

查看原文本刊更多论文

癌症恶病质靶向疗法即将问世--我们能为患者带来哪些临床益处？

一些针对下丘脑和脑干中控制食欲、摄食行为、饱腹感、恶心和呕吐的信号介质的疗法正开始推动癌症恶病质的治疗。然而，还需要明确对患者有意义的临床益处以及支持恶病质治疗获得监管部门批准的主要终点。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nature Reviews Clinical Oncology 医学-肿瘤学

CiteScore

99.40

自引率

0.40%

发文量

114

审稿时长

6-12 weeks

期刊介绍： Nature Reviews publishes clinical content authored by internationally renowned clinical academics and researchers, catering to readers in the medical sciences at postgraduate levels and beyond. Although targeted at practicing doctors, researchers, and academics within specific specialties, the aim is to ensure accessibility for readers across various medical disciplines. The journal features in-depth Reviews offering authoritative and current information, contextualizing topics within the history and development of a field. Perspectives, News & Views articles, and the Research Highlights section provide topical discussions, opinions, and filtered primary research from diverse medical journals.